Metabolomics provides unique value in CVD risk prediction and biomarker identification across populations, offering complementary information to traditional risk factors. It provides direct readout of systemic metabolic state and enable discovery of metabolic pathways associated with the pathophysiology of CVDs. Metabolomics is therefore an important phenotyping modality in CVD research and clinical care.